Titlebook: Rheumatic Diseases and Syndromes Induced by Cancer Immunotherapy; A Handbook for Diagn Maria E. Suarez-Almazor,Leonard H. Calabrese Book 20

Excitotoxin

Aerophagia

Psa617

Sarcoidosis reported recently as adverse events following ICIs. When non-caseating granulomas are identified in the absence of other criteria for the diagnosis of systemic sarcoidosis, the term sarcoid-like reaction is commonly used in the cancer setting. Following ICI therapy, sarcoidosis typically presents w

Regurgitation

開始從未

antenna

Exuberance

Encephalitis

Cancer Immunotherapy in Patients with Preexisting Rheumatic Diseases: Other Rheumatic Autoimmune Disents with pre-existing rheumatic autoimmune diseases. So far, approximately 50 patients with pre-existing rheumatic conditions other than inflammatory arthritis have been reported being treated with ICIs. There are no dedicated guidelines regarding the management of such patients. Owing to concerns

noxious

Management of Rheumatic Immune-Related Adverse Events (irAEs): General Principlesumor immune response. Glucocorticoids are the first-line agent, but they should be used with caution and limited in both dose and duration if possible. Early referral to rheumatology is the key to addressing the issues in these complex patients. More human trials using DMARDs and biologic treatments

昏迷狀態(tài)

Benefit-Risk Considerationsr risk of experiencing adverse events with these agents. Cancer patients with preexisting autoimmune conditions or those who experience rheumatic adverse events with immunotherapy are faced with difficult decisions regarding their treatment. Often, therapeutic gains in survival need to be balanced w